Physician profile
Thaw Tun
NPI 1326142902
$4,101.67
in general payments reported to CMS, 2019-2025
28 companies · $50.01 in 2025
The $50.01 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,801 · 2020: $291 · 2021: $349 · 2022: $886 · 2023: $439 · 2024: $285 · 2025: $50.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $703.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $650.06 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $353.89 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $347.53 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $257.10 | 2019-2024 | Omvoh, Mounjaro |
| Janssen Pharmaceuticals, INC | $237.97 | 2019-2022 | |
| Astellas Pharma US INC | $194.68 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $164.06 | 2019-2021 | |
| Abbvie INC. | $151.57 | 2022-2023 | Qulipta |
| E.R. Squibb & Sons, L.L.C. | $114.58 | 2019-2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.40 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $92.87 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.29 | 2019-2023 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $85.20 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $76.37 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $71.47 | 2024 | Stelara, Tremfya |
| Celgene Corporation | $65.96 | 2024 | Zeposia |
| Almatica Pharma LLC | $55.08 | 2022-2023 | Gralise, Sertraline Hcl, Loreev Xr |
| Amarin Pharma, INC. | $53.95 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $53.25 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.77 | 2019 | |
| Glaxosmithkline, LLC. | $30.71 | 2022-2023 | Trelegy Ellipta |
| Radius Health, INC. | $23.28 | 2019 | |
| Philips North America LLC | $20.16 | 2019 | |
| Exact Sciences Corporation | $18.00 | 2023 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $16.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.14 | 2022 | |
| Neurocrine Biosciences, INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaw Tun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.